Combination therapy in dyslipidemia: where are we now?

@article{Catapano2014CombinationTI,
  title={Combination therapy in dyslipidemia: where are we now?},
  author={Alberico L. Catapano and Michel Farnier and Joanne Micale Foody and Peter P. Toth and Joanne E. Tomassini and Philippe Brudi and Andrew M. Tershakovec},
  journal={Atherosclerosis},
  year={2014},
  volume={237 1},
  pages={319-35}
}
Lowering low-density lipoprotein cholesterol (LDL-C) reduces the risk of cardiovascular disease: each 1.0 mmol/L (38.7 mg/dL) reduction in LDL-C reduces the incidence of major coronary events, coronary revascularizations, and ischemic stroke by approximately 20%. Statins are a well-established treatment option for dyslipidemia, with LDL-C reduction in the range of 27-55%. Several lipid goal-driven guidelines recommend reducing LDL-C to <2.59 mmol/L (100 mg/dL) or <1.81 mmol/L (70 mg/dL) in very… CONTINUE READING